PRGN-2012 is an adenovirus vector-based gene therapy expected to induce immune responses against HPV 6 or 11 infected cells. Findings showed among those treated at the recommended PRGN-2012 dose ...

PRGN-2012 uses a gorilla adenovirus vector to deliver gene therapy to elicit robust T-cell immunity specific to HPV 6 or 11. A second gene therapy candidate that spurs antigen-specific T cell ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

Future Oncol. 2009;5(3):339-357. Clinical trials of oncolytic adenoviral gene therapy in ovarian cancer are due to commence shortly. They will proffer valuable data on toxicity and safety and the ...

and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform. GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity ...